Trial Profile

The Safety and Tolerability After Intravenous Infusion of UMC119-06 in Subjects With Acute Respiratory Distress Syndrome (ARDS)

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs UMC119 06 (Primary)
Indications Adult respiratory distress syndrome
Focus Adverse reactions
Sponsors Meridigen Biotech

Most Recent Events

01 Dec 2023 Planned initiation date changed from 1 Sep 2023 to 1 Jan 2024.
17 Mar 2023 Planned End Date changed from 1 Dec 2023 to 1 Sep 2025.
17 Mar 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Sep 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com